share_log

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Price Dropped 5.6% Last Week; Private Companies Would Not Be Happy

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Stock Price Dropped 5.6% Last Week; Private Companies Would Not Be Happy

浙江沃沃生物製藥有限公司's (SZSE: 300357) 上週股價下跌了5.6%;私營公司不會高興
Simply Wall St ·  03/24 21:58

Key Insights

關鍵見解

  • Zhejiang Wolwo Bio-Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • A total of 3 investors have a majority stake in the company with 57% ownership
  • Insiders own 11% of Zhejiang Wolwo Bio-Pharmaceutical
  • 浙江沃爾沃生物製藥擁有大量私營公司所有權,這表明關鍵決策受廣大公衆股東的影響
  • 共有3名投資者持有該公司的多數股權,所有權爲57%
  • 業內人士持有浙江沃爾沃生物製藥11%的股份

To get a sense of who is truly in control of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are private companies with 39% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

要了解誰真正控制了浙江沃爾沃生物製藥有限公司(深圳證券交易所代碼:300357),了解該業務的所有權結構非常重要。而持有最大份額的集團是擁有39%所有權的私營公司。換句話說,該集團面臨最大的上行潛力(或下行風險)。

And last week, private companies endured the biggest losses as the stock fell by 5.6%.

上週,私營公司遭受了最大的損失,股價下跌了5.6%。

In the chart below, we zoom in on the different ownership groups of Zhejiang Wolwo Bio-Pharmaceutical.

在下圖中,我們放大了浙江沃沃生物製藥的不同所有權群體。

ownership-breakdown
SZSE:300357 Ownership Breakdown March 25th 2024
SZSE: 300357 所有權明細 2024 年 3 月 25 日

What Does The Institutional Ownership Tell Us About Zhejiang Wolwo Bio-Pharmaceutical?

關於浙江沃沃生物製藥,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

We can see that Zhejiang Wolwo Bio-Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Zhejiang Wolwo Bio-Pharmaceutical's earnings history below. Of course, the future is what really matters.

我們可以看到,浙江沃爾沃生物製藥確實有機構投資者;他們持有該公司很大一部分股票。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。如果多家機構同時改變對股票的看法,你可能會看到股價快速下跌。因此,值得在下面查看浙江沃爾沃生物製藥的收益記錄。當然,未來才是真正重要的。

earnings-and-revenue-growth
SZSE:300357 Earnings and Revenue Growth March 25th 2024
SZSE: 300357 2024年3月25日收益和收入增長

Zhejiang Wolwo Bio-Pharmaceutical is not owned by hedge funds. Zhejiang Wolwo Management Consulting Co., Ltd. is currently the largest shareholder, with 39% of shares outstanding. National Council for Social Security Fund is the second largest shareholder owning 9.8% of common stock, and Gengxi Hu holds about 8.3% of the company stock. Gengxi Hu, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board.

浙江沃爾沃生物製藥不歸對沖基金所有。浙江沃爾沃管理諮詢有限公司目前是最大股東,已發行股份的39%。全國社會保障基金委員會是第二大股東,擁有9.8%的普通股,胡更喜持有公司約8.3%的股份。第三大股東胡庚喜也恰好擁有董事會主席的頭銜。

A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 57% stake.

對股東登記冊的更詳細研究表明,前三名股東通過其57%的股份擁有公司的大量所有權。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。儘管有一些分析師的報道,但該公司的報道可能並不廣泛。因此,在未來它可能會引起更多關注。

Insider Ownership Of Zhejiang Wolwo Bio-Pharmaceutical

浙江沃爾沃生物製藥的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。公司管理層經營業務,但首席執行官將對董事會負責,即使他或她是董事會成員。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

Our most recent data indicates that insiders own a reasonable proportion of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.. Insiders own CN¥1.4b worth of shares in the CN¥13b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

我們的最新數據表明,內部人士持有浙江沃沃生物製藥有限公司合理比例的股份。內部人士擁有這家130億元人民幣公司價值14億元人民幣的股份。這很有意義。很高興看到這樣的投資水平。你可以在這裏查看這些內部人士最近是否在買入。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 23% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

包括散戶投資者在內的公衆擁有該公司23%的股份,因此不容易被忽視。儘管這個團體不一定能做主,但它肯定會對公司的運營方式產生真正的影響。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 39%, of the Zhejiang Wolwo Bio-Pharmaceutical stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

看來私營公司擁有浙江沃爾沃生物製藥39%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Zhejiang Wolwo Bio-Pharmaceutical has 1 warning sign we think you should be aware of.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。以風險爲例-浙江沃爾沃生物製藥有 1 個警告信號,我們認爲您應該注意。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但歸根結底,決定這家企業所有者的表現的是未來,而不是過去。因此,我們認爲最好看一下這份免費報告,該報告顯示了分析師是否預測了更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論